Natera Inc. (NTRA)
NASDAQ: NTRAHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NTRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $39.64B
- EPS (TTM)
- -$1.12
- Dividend yield
- None
- 52-week range
- 181.00 – 437.41
- Day range
- 271.85 – 288.41
- Volume / Avg
- 1.38M / 1.77M
- Beta
- —
- Shares outstanding
- 145.00M
52-week range
NTRA stock today
Natera (NTRA) closed at $273.40 on Nov 20, down 5.70% (-$16.52), versus the S&P 500's 3.70% decline. Shares are 37.5% below their 52-week high of $437.41, set on Oct 6, 2026 and 51.0% above the 52-week low of $181.00, in the middle of the past year's range. NTRA is up 19.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 18.5%.
Natera has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Natera
Company profileNatera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Steven Leonard Chapman
- Headquarters
- Austin, TX
- Employees
- 6,135
- IPO year
- 2015
- Website
- natera.com
Financial highlights
Full financialsIn fiscal 2025, Natera generated $2.31 billion in revenue, up 35.9% from fiscal 2024, its 8th consecutive year of revenue growth. Natera reported a net loss of $208.2 million, compared with a loss of $190.4 million a year earlier. Operating margin was -13.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.31B | $1.70B | $1.08B | $820.22M | $625.49M |
| Growth | +35.90% | +56.75% | +31.99% | +31.13% | +59.97% |
| Net income | $-208.16M | $-190.43M | $-434.80M | $-547.80M | $-471.72M |
| EPS (diluted) | $-1.52 | $-1.53 | $-3.78 | $-5.57 | $-5.21 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$410.26+50.06%
- Strong buy 4
- Buy 16
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.42 vs $-0.17
- Surprise
- -147.06%
NTRA news
All NTRA news- Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?NasdaqNTRA, TEM
- ATFV, ZS, MRK, NTRA: Large Outflows Detected at ETFNasdaqATFV, ZS, MRK, NTRA
- Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029Nasdaq
- Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a "Way Station"Nasdaq
- Natera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference TranscriptSeeking Alpha
- Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha
- ATFV, ZS, NTRA, TWLO: Large Outflows Detected at ETFNasdaqATFV, ZS, NTRA, TWLO
- Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer StudyNasdaqNTRA, INCY
Natera peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HUMHumana Inc. | 390.00 | +2.63% | $46.84B | vs NTRA |
| CNCCentene Corporation | 63.78 | -2.74% | $31.58B | vs NTRA |
| LHLabcorp Holdings Inc. | 367.13 | -0.47% | $29.81B | vs NTRA |
| ILMNIllumina Inc. | 192.82 | -3.90% | $29.15B | vs NTRA |
| DGXQuest Diagnostics Incorporated | 258.28 | -0.31% | $28.42B | vs NTRA |
| GHGuardant Health Inc. | 145.83 | +0.16% | $19.73B | vs NTRA |
| MOHMolina Healthcare Inc | 198.39 | -2.43% | $10.36B | vs NTRA |
| HSICHenry Schein Inc. | 83.52 | -1.51% | $9.23B | vs NTRA |
Indexes, lists and sector
Natera stock FAQ
What is Natera's stock price today?
NTRA last traded at $273.40 as of Nov 20, 4:00 PM EST, down 5.70% on the day. Prices are delayed at least 15 minutes.
Who is Natera's CEO?
Mr. Steven Leonard Chapman is the chief executive officer of Natera Inc., which has about 6,135 employees.
What is the NTRA 52-week high?
The 52-week high for NTRA is $437.41 and the 52-week low is $181.00. The stock is currently 37.5% below its high.